Profender

Selected form

Method of action: Anthelmintic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Profender

Quick Facts

Property	Description
Active Ingredients	Emodepside and Praziquantel
Form	Topical solution (Spot-on solution)
Pharmacological Class	Anthelmintic (Broad-spectrum)
General Purpose	Control of mixed parasitic infections (Nematodes & Cestodes)
Unique Feature	Non-invasive dermal route of administration for cats

What Type of Veterinary Medicine is Profender?

Profender is classified as a broad-spectrum therapeutic antiparasitic agent, which is clinically recognized for its effectiveness against a wide range of common feline parasites. The product belongs to the overall Anthelmintic pharmacological class, designed specifically for external application to the skin of cats and kittens. This formulation is delivered as a topical solution, commonly referred to as a spot-on solution, a ready-to-use liquid dispensed via the topical (dermal) route of administration. This administration route is a key differentiating factor, offering a non-invasive alternative to traditional oral dewormers. The medicine is designed to provide a method for managing complex internal parasite loads with simple external application.

Composition and General Purpose

The product's efficacy stems from its two distinct active ingredients: emodepside and praziquantel. Emodepside is a semi-synthetic molecule belonging to the chemical class of octadepsipeptides, which provides the primary Antinematodal effect against roundworms and hookworms. Complementing this, praziquantel is a synthetic molecule, a pyrazinoisoquinoline derivative, which provides the dedicated Cestocide activity against tapeworms. The two active ingredients are presented together in an oil-based solution vehicle for absorption through the skin. The general therapeutic use of Profender is centered on the rapid control and elimination of mixed parasitic infections in felines, offering broad-spectrum efficacy against both intestinal nematode and cestode infestations.

Regulatory References

European Public Assessment Report

What side effects are possible with Profender?

Possible Side Effects and Safety Information

The regulatory safety profile for Profender is characterized by a Very Rare occurrence of documented adverse reactions, meaning they are observed in less than 1 in 10,000 treatments. These effects are generally described as mild and transient in nature.

Key Adverse Reaction Categories

Adverse reactions that have been officially documented are primarily associated with three system-organ classes:

Gastrointestinal Tract and Nervous System: Includes effects such as salivation (hypersalivation), vomiting, ataxia (incoordination), tremor, and lethargy. The occurrence of salivation and vomiting is explicitly linked in regulatory documents to oral exposure—that is, the animal licking the application site immediately following treatment.
Skin and Subcutaneous Tissue: Includes application site reactions such as transient alopecia (temporary hair loss), pruritus (itching), and temporary inflammation (erythema).

Other very rare reports have included anorexia, diarrhoea, and behavioral changes such as hyperactivity or anxiety.

Population-Specific Safety Considerations

The medicine is contraindicated for use in kittens under 8 weeks of age or those weighing less than 0.5 kg. Official regulatory safety statements indicate that the product can be used during pregnancy and lactation.

Other Safety Restrictions

Profender is contraindicated in cases of known hypersensitivity to the active substances (emodepside or praziquantel). Furthermore, one active ingredient, emodepside, is documented as a substrate for P-glycoprotein; this is a high-level safety consideration as co-treatment with certain other drugs could potentially lead to pharmacokinetic interactions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation defines the Profender overdose profile through specific clinical findings and required emergency actions.

Documented Overdose Manifestations

Overdose manifestations observed in regulatory safety studies, particularly following exposure at high-dose multiples or accidental oral ingestion, include the documented clinical signs of salivation, vomiting, and specific neurological signs, such as tremor and abnormal gait (ataxia). These effects are considered to involve the gastrointestinal and nervous systems. The documented overdose classification notes that these symptoms, even when reported at up to ten times the recommended dose in adult cats or five times in kittens, were found to be completely reversible and self-limiting.

Emergency Action and Treatment Constraints

An immediate trigger for seeking assistance is the explicit regulatory mandate to seek medical advice immediately in the event of accidental ingestion or if skin or eye symptoms persist following accidental contact. Management of overdose is defined by the constraint that no known specific antidote is listed in the official labeling. Consequently, any required intervention focuses on observation and supportive measures until the self-limiting signs resolve. The product label must be shown to the physician when seeking assistance.

Therapeutic Uses of Profender

What Profender Treats: Main Uses and Benefits

The primary therapeutic use of this medication is applied in addressing active mixed parasitic infections in cats, relevant in clinical settings for its wide coverage of worm classes. It is commonly used to help with infections caused by major internal parasites, including roundworms and hookworms (Nematodes), and several key types of tapeworms (Cestodes).

The medicine helps ease the symptom clusters that may become intense or disruptive and are associated with a worm burden, such as gastrointestinal discomfort and systemic issues like unexplained weight loss or a dull coat. The benefit to the patient supports improved day-to-day comfort related to digestive function and contributes to easing the overall systemic burden that is associated with internal parasites. Furthermore, this treatment helps address both the adult and the developing immature/larval stages of key nematodes, which may assist with maintaining functional stability in relevant clinical contexts.

This medicine is also applied across domains where additional symptomatic support is needed and is relevant for use in kittens (8 weeks of age and older) and late-term pregnant cats (queens), assisting with maintaining functional stability for vulnerable groups.

Quick Facts: Supportive Assistance for Parasite-Driven Discomfort

Category	Therapeutic Scope
Primary Indication	Mixed internal parasitic infections (Nematodes & Cestodes)
Symptom Domain	Gastrointestinal distress, systemic depletion (e.g., poor coat, weight loss)
Key Benefit	Supports improved comfort and functional stability during periods of heightened symptoms
Target Stages	Adult, immature, and larval stages of key nematodes

Regulatory References

European Medicines Agency product information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Profender (Feline) — Official Regulatory Information

This map summarizes the official population eligibility and non-eligibility rules for Profender Spot-On Solution for Cats, strictly derived from governmental regulatory documentation.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Cats (Feline Species) and kittens at least 8 weeks of age
Populations for whom use is not recommended	Safe use has not been evaluated in cats used for breeding (U.S. label only).
Populations for whom use is contraindicated	Kittens under 8 weeks of age or those weighing less than the minimum threshold (0.5 kg or 2.2 lbs/1 kg, depending on region).
	Cats with known hypersensitivity to emodepside, praziquantel, or excipients.
Pregnancy and lactation eligibility status	Can be used during pregnancy and lactation (European standard); safety has not been evaluated in these groups (U.S. standard).
Eligibility-related restrictions	Use in sick or debilitated animals is restricted and should only proceed based on a formal benefit-risk assessment.
	Heartworm positive cats should receive Profender with caution (U.S. label only).

Resulting Eligibility Structure

Official eligibility statements:

Profender is contraindicated in all kittens under 8 weeks of age and those weighing below the minimum threshold.
A formal contraindication applies to any cat with a known hypersensitivity to emodepside, praziquantel, or any of the product's excipients.
Application to sick or debilitated animals is subject to a conditional use restriction requiring a formal veterinary benefit-risk assessment.

Connection to the overall eligibility profile: Regulatory documents define eligibility based on specific, non-negotiable thresholds related to minimum age and weight, and absolute exclusions for hypersensitivity. Application to vulnerable groups, such as sick, debilitated, or heartworm-positive cats, is restricted, requiring a formal veterinary evaluation as specified in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns based on government regulatory labeling. The interaction profile of Profender is primarily structured around the action of one of its active ingredients, emodepside, as a substrate for a specific drug transporter.

Emodepside is recognized as a substrate for P-glycoprotein (P-gp). This classification establishes the potential for a pharmacokinetic drug interaction when co-administered with other substances that either inhibit or are also substrates of P-gp. These interactions are officially documented as potentially leading to an increased systemic exposure of emodepside.

Regulatory documents identify specific examples of P-gp modulators that could cause this interaction outcome. These include certain antiparasitic macrocyclic lactones (such as ivermectin), as well as specific drugs like erythromycin, prednisolone, and cyclosporine.

Official Interaction Scope

Interaction Type	Modulating Substances	Official Outcome
Transporter-Mediated	P-glycoprotein Inhibitors/Substrates	Risk of Increased Emodepside Exposure

No interactions with food, alcohol, supplements, or herbal products are explicitly documented in the official regulatory information. Furthermore, the labeling does not establish any mandatory timing separation requirements or formally classify any combination as strictly contraindicated.

Mechanism of Action

Pharmacodynamic Mechanism

The pharmacological action of Profender is mediated by two distinct components, each targeting a separate class of parasitic worm. Emodepside targets nematodes (roundworms and hookworms), functioning as a neuromodulator. It acts as an agonist at presynaptic Latrophilin receptors and activates SLO-1 potassium channels in the parasite's nervous system. This initiates a cascade that hyperpolarizes nerve and muscle cell membranes, resulting in profound flaccid paralysis that prevents movement and attachment.

The second component, Praziquantel, targets cestodes (tapeworms). Its mechanism involves rapid disruption of the tapeworm's calcium homeostasis, dramatically increasing the permeability of its cell membranes to Ca^2+ ions. This leads to intense, irreversible spastic paralysis and significant structural damage to the parasite's protective outer layer. The combination employs a parallel mechanistic strategy, utilizing non-overlapping pathways to affect both nematodes and cestodes.

Dosage and Administration Information

Instruction Map: How to use Profender — Administration Guidelines

The application of Profender Topical Solution is governed by instructions detailing the route, dosing, frequency, and administration conditions.

Instruction Domain	Guidelines
Route of administration	The product is restricted to topical (dermal) application as a spot-on solution, applied directly to the skin surface. It is not intended for oral or injectable use.
Dosing schedule	Dosage is determined by the cat’s weight, requiring the administration of a minimum of 3 mg/kg Emodepside and 12 mg/kg Praziquantel, equivalent to 0.14 mL per kilogram of body weight. The single-dose pipette size (Small, Medium, or Large) must be selected to align with the corresponding weight band.
Frequency and timing	Standard treatment involves a single application. However, a specific protocol applies for Aelurostrongylus abstrusus (lungworm), requiring a two-treatment course 14 days apart. Retreatment for common parasites is typically recommended on an intermittent basis (e.g., every three months) where re-infection is likely.
Age-group rules	Use is authorized only for kittens that are a minimum of 8 weeks of age and weigh at least 0.5 kg (2.2 lbs). The product can be used in pregnant and lactating queens.
Preparation specifics	The solution is ready-to-use and requires no dilution or mixing. The entire contents of the unit dose tube must be applied after ensuring the cap seal is broken and the fur is parted to expose the intact skin.

Resulting Procedural Structure

Procedural sequence:

Select the correct weight-banded pipette to deliver the minimum required dose.
Part the fur at the base of the cat's skull until the intact skin is exposed.
Apply the entire contents of the tube directly onto the skin.
Avoid bathing or water immersion until the application site is fully dry.

Connection to the overall use protocol: The use protocol is defined by a topical, single-dose administration strategy delivered to the skin at the base of the skull to standardize product delivery and minimize the risk of oral exposure. This approach mandates adherence to minimum age and weight requirements and includes established schedules for intermittent re-application for maintenance use or specific two-dose courses for certain parasite conditions.

Recent Clinical Evidence

Profender: Recent Clinical Evidence

Profender is a combination medication containing the active ingredients emodepside and praziquantel. Research and regulatory approvals primarily concern its veterinary use as an antiparasitic treatment for cats.

Efficacy and Indication

Clinical trials support the use of the combined topical solution for cats infected with, or at risk of, mixed parasitic infections. Efficacy studies submitted to regulatory bodies demonstrated the single-dose treatment is effective against roundworms (Toxocara cati, Toxascaris leonina), hookworms (Ancylostoma tubaeforme), and tapeworms (Dipylidium caninum, Echinococcus multilocularis, Taenia taeniaeformis). The studies indicated a high percentage of reduction or elimination of these parasites, including certain immature and larval stages.

Safety and Tolerability

Controlled field and laboratory studies have described the safety profile of the topical solution. In a large field safety study involving hundreds of cats, the most frequently reported adverse reactions were self-limiting events, including licking or excessive grooming, scratching at the application site, salivation, and lethargy. These effects are often attributed to the cat attempting to groom the application area. Studies indicate that the product may be used in pregnant and lactating animals, though caution is advised in sick or debilitated cats.

Emerging Research in Human Medicine

While the commercial product is for veterinary use, the ingredient emodepside is currently under investigation for potential use in humans against neglected tropical diseases, such as onchocerciasis (river blindness). Phase I and Phase II clinical trials are being conducted to assess the safety, tolerability, and pharmacokinetics of emodepside tablets in adults with this filarial infection. These investigations aim to evaluate its potential as a treatment for adult worms, distinguishing its study from its approved veterinary application.

How should Profender be stored and disposed of?

Profender Storage and Disposal Requirements

Official Storage Conditions

Profender topical solution must be stored at or below 77°F (25°C), according to official labeling. The product must be protected from freezing to maintain its stability. For unit-dose pipettes, storage is required in the original package to protect the contents from moisture.

Packaging and Safety

The medicine must be kept out of reach of children. The container should be kept tightly closed. The labeled shelf-life of the product as packaged for sale is 3 years.

Disposal Instructions

Any unused Profender or waste material must be disposed of in accordance with local requirements. The product must not be allowed to enter water courses or surface water, as one of its active ingredients, emodepside, is known to be harmful to aquatic organisms.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.